Navegando por Palavras-chave "H1N1"

Agora exibindo 1 - 4 de 4
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    H1N1: pandemia e perspectiva atual
    (Sociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de Citopatologia, 2011-12-01) Bellei, Nancy Cristina Junqueira [UNIFESP]; Melchior, Thaís Boim [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    The swine origin influenza virus A/CALIFORNIA/04/2009 (H1N1) was first detected in Mexico and determined the 2009 influenza pandemic. In August 2010, World Health Organization (WHO) declared the beginning of the post-pandemic period. This last pandemic was distinctly different from previous ones. The virus emerged from genetic rearrangement in non-human mammalian host. Moreover, its inter-species transmission is fully reported. However, it affected human population differently from previous pandemic viruses (1918, 1957, 1968), with increased morbidity and mortality among children and young adults. Currently, the virus has a seasonal pattern in the same way as influenza A H3N2 and influenza B, maintaining the same pathogenicity profile, clinical spectrum and sensitivity to antiviral agents. The strain was included in the annual trivalent seasonal vaccine formulation, mainly for risk groups, which are more vulnerable to complications caused by different influenza strains.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Morbimortality of Pandemic Influenza A H1N1 Infection in Kidney Transplant Recipients Requiring Hospitalization: A Comparative Analysis With Nonimmunocompromised Patients
    (Lippincott Williams & Wilkins, 2012-01-15) Camargo, Luis Fernando A. [UNIFESP]; Sandes-Freitas, Taina V. de [UNIFESP]; Silva, Camila D. R. [UNIFESP]; Bittante, Carolina D. [UNIFESP]; Ono, Gislaine [UNIFESP]; Correa, Luci [UNIFESP]; Silva, Moacyr [UNIFESP]; Bellei, Nancy Cristina J. [UNIFESP]; Goto, Janaina M. [UNIFESP]; Medeiros, Eduardo A. S. [UNIFESP]; Gomes, Pollyane S. [UNIFESP]; Medina-Pestana, Jose O. [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Hosp Rim & Hipertensao
    Background. Clinical and epidemiological data of pandemic influenza A H1N1 infection in solid-organ transplant recipients have been described, but scarce data compare these outcomes with nonimmunocompromised patients.Methods. We retrospectively reviewed and compared the clinical presentation, morbidity, and mortality of all kidney transplant (KT) and nonimmunocompromised (non-KT) patients admitted for at least 12 hr with a diagnosis of pandemic influenza A H1N1 infection in a single hospital complex during the 2009 pandemic.Results. There were 22 patients in the KT group (29.3%) and 53 in the non-KT group (70.7%). the prevalence of diabetes was higher in KT group (27.3% vs. 5.7%) while chronic pulmonary disease was more frequent in non-KT group (34% vs. 9.1%). Clinical and radiological presentations and duration of disease were similar between the two groups. the incidence of acute renal failure was higher among KT patients (40.9% vs. 17%). No differences in the rate of intensive care unit admission (22.7% vs. 22.6%) or hospital mortality (9.1% vs. 7.5%) were observed. for the overall population, poor outcome, defined as intensive care unit admission or death, was associated with in-hospital acquisition (relative risk [RR] = 42.6 [95% confidence interval {95% CI} 2.2-831.9], P = 0.003), symptom onset more than 48 hr (RR = 12.17 [95% CI 1.3-117.2], P = 0.007), and acute renal failure (RR = 11.8 [95% CI 2.9-48.8], P = 0.001). Among KT recipients, in-hospital acquisition was the only covariate associate with poor outcome (RR = 30.0 [95% CI 2.1421.1], P = 0.004).Conclusions. No significant differences in morbidity and mortality were observed comparing KT and non-KT patients infected with pandemic H1N1 influenza A virus.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial
    (Oxford Univ Press Inc, 2014-08-15) Nolan, Terry; Roy-Ghanta, Sumita; Montellano, May; Weckx, Lily [UNIFESP]; Ulloa-Gutierrez, Rolando; Lazcano-Ponce, Eduardo; Kerdpanich, Angkool; Palazzi Safadi, Marco Aurelio; Cruz-Valdez, Aurelio; Litao, Sandra [UNIFESP]; Lim, Fong Seng; Mascarenas de Los Santos, Abiel; Rodriguez Weber, Miguel Angel; Tinoco, Juan-Carlos; Hernandez-de Mezerville, Marcela; Faingezicht, Idis; Kosuwon, Pensri; Lopez, Pio; Borja-Tabora, Charissa; Li, Ping; Durviaux, Serge; Fries, Louis; Dubin, Gary; Breuer, Thomas; Innis, Bruce L.; Vaughn, David W.; Univ Melbourne; GlaxoSmithKline Vaccines; Novavax; Mary Chiles Gen Hosp; De La Salle Hlth Sci Inst; Res Inst Trop Med; Universidade Federal de São Paulo (UNIFESP); Assoc Fundo Incent Pesquisa; Inst Costarricense Invest Clin; Natl Inst Publ Hlth Mexico; Univ Autonoma Nuevo Leon; Inst Nacl Pediat Mexico; Hosp Gen Durango; Phramongkutklao Hosp; Khon Kaen Univ; Natl Healthcare Grp Polyclin; Ctr Estudios Infect Pediat
    Background. the vaccine efficacy (VE) of 1 or 2 doses of AS03-adjuvanted influenza A(H1N1) vaccine relative to that of 2 doses of nonadjuvanted influenza A(H1N1) vaccine in children 6 months to <10 years of age in a multinational study conducted during 2010-2011.Methods. A total of 6145 children were randomly assigned at a ratio of 1: 1: 1 to receive 2 injections 21 days apart of A/California/7/2009(H1N1)-AS03 vaccine at dose 1 and saline placebo at dose 2, 2 doses 21 days apart of A/California/7/2009(H1N1)-AS03 vaccine (the Ad2 group), or 2 doses 21 days apart of nonadjuvanted A/California/7/2009(H1N1) vaccine (the NAd2 group). Active surveillance for influenza-like illnesses continued from days 14 to 385. Nose and throat samples obtained during influenza-like illnesses were tested for A/California/7/2009 (H1N1), using reverse-transcriptase polymerase chain reaction. Immunogenicity, reactogenicity, and safety were assessed.Results. There were 23 cases of confirmed 2009 pandemic influenza A(H1N1) (A[H1N1]pdm09) infection for the primary relative VE analysis. the VE in the Ad2 group relative to that in the NAd2 group was 76.8% (95% confidence interval, 18.5%-93.4%). the benefit of the AS03 adjuvant was demonstrated in terms of the greater immunogenicity observed in the Ad2 group, compared with the NAd2 group.Conclusion. the 4-8-fold antigen-sparing adjuvanted pandemic influenza vaccine demonstrated superior and clinically important prevention of A(H1N1)pdm09 infection, compared with nonadjuvanted vaccine, with no observed increase in medically attended or serious adverse events. These data support the use of adjuvanted influenza vaccines during influenza pandemics.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Swine-Origin Influenza A (H1N1) Viral Infection: Thoracic Findings on CT
    (Amer Roentgen Ray Soc, 2011-06-01) Marchiori, Edson; Zanetti, Glaucia; D'Ippolito, Giuseppe [UNIFESP]; Verrastro, Carlos Gustavo Yuji [UNIFESP]; Meirelles, Gustavo de Souza Portes [UNIFESP]; Capobianco, Julia [UNIFESP]; Rodrigues, Rosana Souza; Universidade Federal Fluminense (UFF); Universidade Federal do Rio de Janeiro (UFRJ); Universidade Federal de São Paulo (UNIFESP); DOr Inst Res & Educ
    OBJECTIVE. the purpose of this article is to illustrate and describe various CT manifestations of swine-origin influenza A (H1N1) viral infection.CONCLUSION. the imaging findings seen in patients with H1N1 infection include consolidations, ground-glass opacities, interlobular septal thickening, small nodules, and findings suggestive of small airways disease, among others. Definitive diagnosis is based on correlation of the CT findings with the clinical symptoms and laboratory test results.